Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study - Report - MDSpire
Advertisement
Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study
Effectiveness and Safety of Maintenance Therapy with PARP Inhibitors in Older Patients with Ovarian Cancer
Overview
This study evaluates the effectiveness and safety of PARP inhibitors olaparib and niraparib as maintenance therapy in older patients with ovarian cancer. The findings indicate favorable progression-free survival (PFS) outcomes and manageable safety profiles in this population.
Background
Ovarian cancer remains a leading cause of cancer-related mortality among women, particularly in older patients who often present with advanced disease. As the population ages, understanding the efficacy and safety of treatments like PARP inhibitors in this demographic is crucial for optimizing care. This study addresses a significant gap in the literature regarding the use of PARP inhibitors in elderly patients.
Data Highlights
Parameter
Value
Mean Age
70.14 ± 4.63 years
Median PFS (1L group)
24 months
Adverse Events (Anemia)
22.7% (Olaparib)
Adverse Events (Thrombocytopenia)
11.1% (Niraparib)
Key Findings
35.7% of patients received olaparib, while 60.7% received niraparib.
Median progression-free survival (mPFS) was 24 months for the first-line maintenance therapy group.
Factors associated with longer PFS included CA125 levels, CR status, BRCA mutation status, and R0 at initial surgery.
In the PSR group, mPFS was not reached for patients with PSR ≥12 months.
Anemia and thrombocytopenia were the most common grade 3–4 adverse events for olaparib and niraparib, respectively.
Clinical Implications
The results suggest that PARP inhibitors can be effectively used as maintenance therapy in older patients with ovarian cancer, with specific clinical factors predicting better outcomes. Clinicians should consider these factors when selecting treatment options for elderly patients.
Conclusion
PARP inhibitors demonstrate favorable outcomes and manageable safety profiles in elderly patients with ovarian cancer, highlighting the need for tailored treatment approaches in this growing population.
